Diasorin soars on the stock market after confirming its 2026 guidance, a move that surprised the market, considering the below-expected numbers recorded in the first quarter. At midday, the shares of the immunodiagnostics company advances by 7,9% to 68,22 euros per share, after having touched a maximum of 69,44 dollars, against a FTSE Mib up 0,4%.
Diasorin: revenues and profits decline in the quarter
Diasorin closed the first quarter with revenues of 287 million, down 3% at constant exchange rates and 8% at current exchange rates, while net profit stood at 38 million, down 28% (with a 13% impact on revenues).
The adjusted EBITDA was 90 million, (-13% at constant exchange rates and -16% at current exchange rates). The numbers presented today disappointed analysts' expectations, but allowed Diasorin to confirm estimates for the 2026 financial year revenue growth between +5% and +6% and an adjusted EBITDA margin between 32%-33%.
The judgment of the analysts
Weighing on the performance of the first three months of the financial year, says Intermonte, were "unfavorable factors of a transitory nature“such as a lackluster flu season, the reduction in QuantiFeron inventories due to the decline in demand for tuberculosis tests related to immigration visas” in the US. However, the reason for confirming the 2026 guidance is “a f"great acceleration" expected "in the second half of the year – continues the investment bank – thanks to the authorization of Plex Gi (a diagnostic system for the detection of gastrointestinal viruses), the increase in production of the Nes diagnostic platform and the launch phase of
Meanwhile, the anticipation for the new business plan, which Diasorin will present next May 20th. But the following will also be crucial: competitors' movesAt tomorrow's Investor Day, Swiss company Roche could announce the launch of a latent tuberculosis test in Europe, with direct implications for QuatiFeron. In light of this, Intermonte has confirmed its "Neutral" rating on the stock, raising its target price from 73 to 74 euros.
For Deutsche Bank – which has a target price of 63 euros for Diasorin – "Diasorin's first-quarter results were below expectations in terms of revenue, but above expectations in terms of adjusted EBITDA, and highlighted a further deterioration in growth and profitability." Despite confirming the guidance, analysts remain "skeptical about the expected recovery" in the coming quarters, as well as about the easing of several unfavorable factors.
Equita is on the same wavelength, stating that Diasorin's recovery "will largely depend on the respiratory season and a normalization of demand for immunodiagnostics, factors on which we currently believe visibility is still limited." Analysts therefore confirm their "hold" recommendation with a target price of 70 euros.
Finally Banca Akros The company gives the stock an “accumulated” rating and a target price of 76 euros, highlighting that, even with “better-than-estimated sales” in the first quarter, “profitability is better than expected.”
